Actively Recruiting
Evaluating ABO-101 Safety and Effects in Primary Hyperoxaluria Type 1 A Dose Escalation Study in Children and Adults
Led by Arbor Biotechnologies · Updated on 2026-10-19
23
Participants Needed
7
Research Sites
726 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ABO-101 for safety, tolerability, how the body processes it, and its effects in people with primary hyperoxaluria type 1 PH1, a rare genetic condition. The study is a Phase 12 trial sponsored by Arbor Biotechnologies and consists of two main study periods to carefully assess the medication in adults and children. In the first study period, adults receive a single ascending dose to determine the best dose in Part A. Then, in Part B, children receive the recommended dose identified from adults. After these initial treatments, participants enter a long-term monitoring phase to meet local and national requirements and observe ongoing effects. Participants will undergo intravenous infusions of ABO-101, followed by regular evaluations including safety checks for any side effects up to six months, and measurements of urinary oxalate and plasma glycolate levels. Kidney function and immune responses to the drug will also be monitored over 12 to 24 months. The total study duration includes initial dosing and extended follow-up to understand the treatments impact and safety over time.
CONDITIONS
Brief Title
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
Research Team
D
Daniel Ory, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here